ReviewHealth science reports2025
Global Profile of Drug Resistance Related to
Review in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Tetracycline for Helicobacter pylori eradication: a narrative review from quadruple to dual therapy.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
- Article
- Burden, clinical impact, and primary antimicrobial resistance profiles of Helicobacter pylori infections in Cameroon: A systematic review and meta-analysis.PLOS global public health · 2026Article
- Antibiotic resistance and associated gene mutations ofFrontiers in cellular and infection microbiology · 2026Article
- Helicobacter pylori in Turkish Children with Dyspepsia: Diagnosis, Prevalence, Genotyping and Antibiotic Resistance - Correspondence.Indian journal of pediatrics · 2026Article
- Potassium-competitive acid blockers forFrontiers in cellular and infection microbiology · 2026Review
- Global Profile of Drug Resistance Related toHealth science reports · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: The increasing prevalence of antibiotic-resistant Methods: A systematic literature search was conducted across ISI Web of Science, PubMed, Scopus, and Google Scholar, encompassing the period from the inception of each database up to December 2021. Eligible studies reporting primary antibiotic resistance in Results: One hundred eleven teens were included in this meta-analysis, and 36,021 isolates of this bacterium were evaluated. The resistance rate was reported 25.6%, 30.9%, 2.5%, 2.0%, 12.1%, 6.9%, 1.9%, 0.5%, and 9.1%, for clarithromycin, metronidazole, amoxicillin, tetracycline, levofloxacin, ciprofloxacin, furazolidone, nitrofurantoin, and rifampin respectively. Furthermore, the pooled prevalence of primary multidrug resistant isolates was 4.5%. Conclusion: This meta-analysis reveals a significant global burden of primary resistance to clarithromycin and metronidazole in pediatric
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.